084990.KQ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 01:53):

Stats
Today's Volume	123 201
Average Volume	499 516
Market Cap	229.16B
EPS	KRW0 ( 2024-02-13 )
Next earnings date	( KRW0 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW6.70 (0.14%)

Volume Correlation

Long: -0.05 (neutral)

Short: -0.17 (neutral)

Signal:(61.374) Neutral

Helixmith Co., Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Helixmith Co., Ltd Correlation - Currency/Commodity

0.20
( neutral )

0.50
( neutral )

-0.82
( strong negative )

0.24
( neutral )

0.18
( neutral )

-0.63
( weak negative )

Helixmith Co., Ltd Financials

Annual	2023
Revenue:	KRW4.20B
Gross Profit:	KRW-8.57B (-204.02 %)
EPS:	KRW-1 543.76

Q4	2023
Revenue:	KRW538.66M
Gross Profit:	KRW-2.61B (-484.17 %)
EPS:	KRW-875.61

Q3	2023
Revenue:	KRW1.09B
Gross Profit:	KRW-2.01B (-183.72 %)
EPS:	KRW-199.26

Q2	2023
Revenue:	KRW1.10B
Gross Profit:	KRW-2.10B (-191.28 %)
EPS:	KRW-205.96

Financial Reports:

No articles found.

Helixmith Co., Ltd

Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. The company's pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer; and VM501, a re-engineered form of interleukin 11 targeting chemotherapy-induced thrombocytopenia. Its clinical trials biologics comprise VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. Helixmith Co., Ltd was incorporated in 1996 and is headquartered in Seoul, South Korea.